Showing: 1 - 7 of 7 RESULTS

Fitness tech company JAXJOX raises $10M as it gets ready to ship AI-enabled workout system

The JAXJOX InteractiveStudio exercise system. (JAXJOX Photo)

© Provided by Geekwire
The JAXJOX InteractiveStudio exercise system. (JAXJOX Photo)

JAXJOX, the Redmond, Wash.-based fitness technology company, has raised $10 million in a new funding round to help pay for the research and development of its signature InteractiveStudio workout equipment.


Load Error

The Series A round included investors Dowgate Capital Ltd. and entrepreneur Nigel Wray, and brings total funding to $17 million for the 3-year-old company.

JAXJOX is getting set to release its InteractiveStudio smart gym, a home fitness system that includes digitally adjustable weights, AI-enabled connected tech built into the equipment, and live and on-demand classes.

With connected tech built into individual pieces of free-weight equipment, such as a smart kettlebell, users don’t have to stand a certain distance from a screen to have form and motion tracked.

“By monitoring performance metrics and using AI, we can give users a more holistic view of their health and provide recommendations on improving their wellbeing,” founder and CEO Stephen Owusu said in a news release. “We believe that, for users, tracking power generated while lifting will become as important as tracking your heart rate while running.”

The InteractiveStudio is available for pre-order on the JAXJOX website and retails for $2,199 with a $39 monthly subscription. The system will also sell as part of an exclusive retail partnership this fall with Best Buy.

Continue Reading

Source Article

The Best Fitness Tech To Buy at Walmart’s Major Sale, From Apple Watches to Treadmills

Treadmills and Apple watches aren’t exactly inexpensive, which means any time they go on sale is so incredibly exciting, making the investment all the more worthwhile. Walmart is in the midst of a huge sale where you can get fitness tech and tools at a massive discount.

Walmart’s major sale on fitness items is perfect for anyone who is looking to outfit their home gym or introduce more tech into their routine. Shop the very best deals below.

a person using a cell phone: Walmart fitness

© Photo: Stocksy / Mattia
Walmart fitness

The best fitness tech to buy at Walmart

1. Apple Watch Series 3 GPS, $169

icon: Apple Watch Series 3 GPS, walmart fitness

© Provided by Well+Good
Apple Watch Series 3 GPS, walmart fitness

Originally released in September 2017, the Apple Watch Series 3 normally sells for $199. This watch allows you to measure your workouts, track and share your daily activity, better manage everyday stress, and monitor your heart rate more effectively. You can also sync it with your favorite playlists and use it to stay in touch with friends and family. This watch is available in white and black.

Shop now: Apple Watch Series 3 GPS, $169

To learn more about wearables, watch What the Wellness Host Ella Dove try them out:

2. Zimtown Ktaxon Fitness Blue Yoga Stability Balance Trainer Ball with Resistance Bands, $55

a close up of a pot: Zimtown Ktaxon Fitness Blue Yoga Stability Balance Trainer Ball with Resistance Bands

© Provided by Well+Good
Zimtown Ktaxon Fitness Blue Yoga Stability Balance Trainer Ball with Resistance Bands

A stability ball can make all of your workouts harder and more effective. Add in the resistance bands and this tool is like a mini gym. Use just the ball for crunches à la Kate Hudson or stand on it while doing bicep curls or arm raises to work your arms and core at the same time.

Shop now: Zimtown Ktaxon Fitness Blue Yoga Stability Balance Trainer Ball with Resistance Bands, $55

3. Echelon Connect Sport Indoor Cycling Exercise Bike, $499

a close up of a motorcycle: Echelon Connect Sport Indoor Cycling Exercise Bike

© Provided by Well+Good
Echelon Connect Sport Indoor Cycling Exercise Bike


Originally priced at $599, this Echelon indoor cycling bike is perfect for getting your cardio in at home. The bike comes with six months of free access to the Echelon Fit App, where you’ll have access to over 1,600 cycling classes of all fitness levels and music genres. You can filter by length, music, language, instructor, and more to find the best class for you.

Shop now: Echelon Connect Sport Indoor Cycling Exercise Bike, $499

4. Apple Air Pods, $129

Apple Air Pods

© Provided by Well+Good
Apple Air Pods

These earbuds took over as soon as they launched, and for good reason. Having the comfort of earbuds without the hassle of a cord is a game-changer. This pair, typically sold for $159, comes with a standard charging case. The AirPods with Wireless Charging Case ($160) and the AirPods Pro ($199) are also on sale.

Shop now: Apple AirPods, $129

5. Bose QuietComfort 35 Wireless Noise Cancelling Headphones II, $299

a close up of electronics: Bose QuietComfort 35 Wireless Noise Cancelling Headphones II

© Provided by Well+Good
Bose QuietComfort 35 Wireless Noise Cancelling Headphones II

If you prefer headphones to earbuds, this pair

5 must-know leaders in medicine, science and tech

Now more than ever, it is undeniable how integral science and research have become to public health. Nationwide, doctors, scientists and experts are working around the clock to find the most up-to-date and reliable information to prevent and stop the spread of Covid-19.

Here are five must-know women who are shattering ceilings, making groundbreaking discoveries, and spreading public awareness during the global pandemic.

Joy Buolamwini

Joy Buolamwini, founder of Algorithmic Justice League, speaks in New York on March 27, 2019.Bess Adler / Bloomberg via Getty Images

Joy Buolamwini is the founder of the Algorithmic Justice League (AJL), a computer scientist and an expert in artificial intelligence bias. Four years ago, when Buolamwini was a graduate student at MIT’s Media Lab, she began looking into the racial and gender disparities in commercially-available facial recognition technologies. Her research culminated in two groundbreaking, peer-reviewed studies, published in 2018 and 2019, that revealed how systems used by Amazon, IBM, Microsoft and others were unable to classify darker female faces as accurately as those of white men—essentially shattering the myth of machine neutrality.

Buolamwini’s research helped persuade these companies to put a hold on facial recognition technology until federal regulations were passed. Through her nonprofit AJL, she has testified before lawmakers at the federal, state and local levels about the dangers of using facial recognition technologies with no oversight.

In the aftermath of the police killing of George Floyd, Buolamwini has called for a complete halt to police using such facial surveillance and is providing activists with resources and tools to demand regulation.

It’s not easy to go up against some of the biggest tech companies when you know they can deploy all of their resources against you. I am still very aware that I am a young Black woman in America. And in the field of AI, the people I was aiming to evaluate held all the purse strings. – Joy Buolamwini

Dr. Kizzmekia Corbett

Dr. Kizzmekia Corbett, left, senior research fellow and scientific lead for coronavirus vaccines and immunopathogenesis team in the Viral Pathogenesis Laboratory, talks with President Donald Trump as he tours the Viral Pathogenesis Laboratory at the National Institutes of Health in Bethesda, Md., on March 3, 2020.Evan Vucci / AP

Dr. Corbett is a viral immunologist and research fellow in the Vaccine Research Center (VRC) at the National Institute of Allergy and Infectious Diseases (NIAID). She went viral on social media this spring after news broke that Dr. Corbett, a Black female scientist, was leading the team of researchers working on a Covid-19 vaccine at the NIH.

Dr. Corbett’s passion for science stems from her summer break during high school, when she began working in a chemistry lab at the University of North Carolina. After being paired with Black grad student and future mentor, Albert Russell, she was able to see how it was possible for her to impact science through representation. Dr. Corbett has stressed the importance of mentors and advocates, crediting her boss, Dr. Barney Graham,

Hillel’s Tech Corner: MeMed: Bringing data to medicine

It is 2020 and we have self-driving cars, autonomous drones, and advanced robotics. Yet, when you go to the doctor with a headache, the ability to differentiate between a viral and bacterial infection is significantly harder than it should be. The result is often the prescription of antibiotics that are not actually needed.Antibiotic misuse contributes to the rise of antimicrobial resistance, which causes 700,000 deaths annually worldwide, a figure that is projected to increase to 10 million by 2050. By giving patients antibiotics they don’t need, more harm is being done than good. The ability to analyze data and extract deep and actionable insights into the nature and severity of a patient’s condition is imperative.Meet MeMed, an Israeli company founded in 2009, now with more than 70 employees, and offices in Haifa, Israel and the US.MeMed raised $100M+ from leading VCs and insurers, and is the recipient of $35M+ in grants, including those from the US Department of Defense and the EU Commission. Their investors include: Ping An Global Voyager Fund, Foxconn, Caesarea Medical Holdings, Clal Insurance, Phoenix Insurance, OurCrowd, Social Capital, WTI and Horizons Ventures.MeMed is a leader in host immune response technology and is focused on providing physicians with tools to improve patient management. Their mission is to decode and translate the immune system’s complex signals into actionable insights that can be used to transform the way infectious diseases and inflammatory disorders are diagnosed and treated. Their technology platform makes it possible to conduct highly sensitive, rapid, multiplexed protein measurements at the point of need that previously could only be done on central lab equipment. Their test, MeMed BV, measures host-immune response proteins from a small sample of blood, and then applies machine learning to accurately distinguish between bacterial and viral infections.As of late, the company is using its technology to analyze and interpret the unique expression of three biomarker proteins in response to COVID-19 infection to provide insights into disease severity and risk stratification, in addition to monitoring patient response to treatment. They are currently running various studies around early detection of disease severity that may support physicians in their medical decisions.MeMed is actively collaborating with clinical centers in the US, Israel, Germany and Asia. They collected more than 1,000 samples from COVID-19 patients, which they plan to use to develop a test for predicting how severe a patient’s infection will be, so people at high risk of severe cases can be prioritized for treatment. They also launched a collaboration with a Dutch medical center, sampling hundreds of asymptomatic healthcare workers.While evidence shows that only a small percentage of COVID-19 patients need antibiotics to treat subsequent bacterial co-infections, when the coronavirus first emerged, doctors were left scrambling with how to manage patients. With no drug proven for treating COVID-19 patients, many turned to antibiotics, a concerning trend likely to lead to higher bacterial resistance rates.MeMed was co-founded by Dr. Eran Eden and Dr. Kfir Oved.Eden has been the

Health tech firm testing coronavirus treatments hit by ransomware attack

 A ransomware attack on a health tech firm has slowed some clinical trials, including some involving treatments and vaccines for the coronavirus.

The target was a Philadelphia company that sells software used in hundreds of clinical trials, according to the New York Times.

No patients were affected.


The attack on eResearchTechnology (ERT) began two weeks ago when employees discovered they were locked out of their data by ransomware.

The companies hit were IQVIA, a contract research organization helping to manage AstraZeneca’s Covid vaccine trial, and Bristol Myers Squibb, which is leading a consortium of companies to develop a quick test for the virus.

ERT has not said how many clinical trials were affected.


The company was involved in three-quarters of trials that led to drug approvals by the Food and Drug Administration last year, according to its website.

On Friday, Drew Bustos, ERT’s vice president of marketing, confirmed that ransomware had seized its systems Sept. 20.


As a precaution, Bustos said, the company took its systems offline that day and notified outside cybersecurity experts as well as the FBI.

The company said it was too early to say who was behind the attack.

A spokesman declined to say whether the company paid its extortionists.


The incidents followed more than 1,000 ransomware attacks on U.S. cities, counties and hospitals over the past 18 months, according to the Times.

Source Article

Clinical Trials Hit by Ransomware Attack on Health Tech Firm

The incidents also follow more than a thousand ransomware attacks on American cities, counties and hospitals over the past 18 months. The attacks, once treated as a nuisance, have taken on greater urgency in recent weeks as American officials worry they may interfere, directly or indirectly, with the November election.

A ransomware attack in Germany resulted in the first known death from a cyberattack in recent weeks, after Russian hackers seized 30 servers at University Hospital Düsseldorf, crashing systems and forcing the hospital to turn away emergency patients. As a result, the German authorities said, a woman in a life-threatening condition was sent to a hospital 20 miles away in Wuppertal and died from treatment delays.

ERT’s clients at IQVIA and Bristol Myers Squibb said they had been able to limit problems because they had backed up their data, but the attack forced many clinical trial investigators to move to pen and paper.

In a statement, IQVIA said that the attack had “had limited impact on our clinical trials operations,” and added, “We are not aware of any confidential data or patient information, related to our clinical trial activities, that have been removed, compromised or stolen.”

Pfizer and Johnson & Johnson, two companies working on a coronavirus vaccine, said their coronavirus vaccine trials had not been affected.

“ERT is not a technology provider for or otherwise involved in Pfizer’s Phase 1/2/3 Covid-19 vaccine clinical trials,” Amy Rose, a spokeswoman for Pfizer, said.

Companies and research labs on the front lines of the pandemic have been repeat targets for foreign hackers over the past seven months, as countries around the world try to gauge one another’s responses and progress in addressing the virus. In May, the F.B.I. and the Department of Homeland Security warned that Chinese government spies were actively trying to steal American clinical research through cybertheft.

Source Article

Insilico Medicine to present at Leveraging Intelligent Tech for Drug Development


IMAGE: Leveraging intelligent tech for drug development.
view more 

Credit: Insilico Medicine

Wednesday, September 30, 2020 – Insilico Medicine, a global leader in artificial intelligence for drug discovery and development, will present its latest results in modern and next-generation AI for drug discovery and productive longevity at the Live Leveraging Intelligent Tech for Drug Development Forum on September 30, 2020.

AI, automation and data integration are condensing the timeline from discovery to development and solving biological problems. On September 30th, leaders from biotech and pharma will discuss specific examples of how these technological advancements are reshaping the drug development landscape.

While technology continues to revolutionize biotech, pharmaceutical companies are investing heavily in modernizing internally to embrace and embed these innovations throughout their organizational structure and culture. On the clinical trial front, not only are sponsors pressed to have remote and decentralized designs for their trial models due to the ongoing COVID19 pandemic, but regulators have openly expressed their willingness to consider creative new ideas for trial design, including wearable technology for remote data capture. Meanwhile in the workforce, competition is fierce to recruit and maintain the best talent and to understand how the role of the scientist is evolving to embrace the future of tech-enabled biopharma.

“We are thrilled to have CEO Alex Zhavoronkov address stakeholders at the upcoming digital forum on Leveraging Intelligent Tech for Drug Development on September 30th, hosted by Unite Life Sciences. Insilco Medicine’s work in the use of AI in drug discovery for Sars-CoV-2 and the ongoing COVID19 Global Pandemic offers remarkable insight to participants in the forum, which convenes senior decision makers, investors, and innovators in pharma, biotech and venture capital to examine real-case scenarios for accelerating drug discovery and modernizing clinical trials with data & automation. Unite Life Sciences is the dedicated life science division of IQPC US. Their digital content & forums provide a platform to drive stakeholder engagement, collaboration, and transformational change in biopharma.” said Nicole Hayes, Managing Director, Unite Life Sciences.

“I am very happy to present at Leveraging Intelligent Tech for Drug Development – a great event to gain insight on how industry can successfully align innovation in science, design, regulatory process and patient-centricity.” said Alex Zhavoronkov, Ph.D., Founder and CEO of Insilico Medicine.


For further information, images or interviews, please contact: [email protected]m.

About Insilico Medicine

Since 2014 Insilico Medicine is focusing on generative models, reinforcement learning (RL), and other modern machine learning techniques for the generation of new molecular structures with the specified parameters, generation of synthetic biological data, target identification, and prediction of clinical trials outcomes. Recently, Insilico Medicine secured $37 million in series B funding. Since its inception, Insilico Medicine raised over $52 million, published over 100 peer-reviewed papers, applied for over 25 patents, and received multiple industry awards. Website

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.